Literature DB >> 10618697

Evidence for the genetic role of human leukocyte antigens in low frequency DRB1*1501 multiple sclerosis patients in Israel.

A Karni1, Y Kohn, C Safirman, O Abramsky, L Barcellos, J R Oksenberg, E Kahana, D Karussis, J Chapman, C Brautbar.   

Abstract

A strong association exists between multiple sclerosis (MS) and the DRB1*1501 haplotype, in most populations. Linkage of Multiple Sclerosis (MS) with the MHC or HLA region on chromosome 6p21 has previously been observed in DRB1*1501 positive MS families. A group of 13 Israeli multiplex MS families with a very low frequency of DRB1*1501 haplotype were examined in this study. Association and a linkage test were performed in order to identify a non-DRB1*1501 effect of HLA on susceptibility for MS. MS multiplex families and healthy controls were molecularly typed for six highly polymorphic markers located within the MHC region: DRB1, DQA1 and DQB1, BAT-2, MIB and D6S248. Data analyses included: (a) an association study comparing the patient group with both healthy relative, and healthy control groups (b) a transmission test for linkage disequilibrium (TDT) of the MS-associated alleles in the multiplex families, and (c) multipoint non-parametric linkage (NPL) and parametric LOD score analyses using the GENEHUNTER program. The DRB1*1303 allele was significantly more frequent among the MS patients. There was a trend towards transmission disequilibrium of DRB1*1303, but was not statistically significant. Allele sharing and LOD score analyses revealed no evidence for linkage. The high frequency of DRB1*1303 observed in our family patients provides evidence to support the association with this allele that previously described in sporadic non-Ashkenazi MS patients. Thus, DRB1*1303 may serve as genetic risk factor for MS. Our study exemplifies the genetic heterogeneity in MS as there is a genetic effect of HLA on MS susceptibility in our low frequency DRB1*1501 patients.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10618697     DOI: 10.1177/135245859900500i607

Source DB:  PubMed          Journal:  Mult Scler        ISSN: 1352-4585            Impact factor:   6.312


  6 in total

1.  The presence of glutamic acid at positions 71 or 74 in pocket 4 of the HLA-DRbeta1 chain is associated with the clinical course of multiple sclerosis.

Authors:  J M Greer; M P Pender
Journal:  J Neurol Neurosurg Psychiatry       Date:  2005-05       Impact factor: 10.154

Review 2.  The immunogenetics of multiple sclerosis: A comprehensive review.

Authors:  Jill A Hollenbach; Jorge R Oksenberg
Journal:  J Autoimmun       Date:  2015-07-02       Impact factor: 7.094

3.  HLA class II alleles in patients with multiple sclerosis in the Biscay province (Basque Country, Spain).

Authors:  Oscar Fernández; Alfredo R-Antigüedad; María Jesús Pinto-Medel; Mari Mar Mendibe; Nestor Acosta; Begoña Oliver; Miguel Guerrero; Marcos Papais-Alvarenga; Victoria Fernández-Sánchez; Laura Leyva
Journal:  J Neurol       Date:  2009-12       Impact factor: 4.849

4.  Analysis of HLA DR2&DQ6 (DRB1*1501, DQA1*0102, DQB1*0602) haplotypes in Iranian patients with multiple sclerosis.

Authors:  Mojdeh Ghabaee; Asghar Bayati; Shahla Amri Saroukolaei; Mohamad Ali Sahraian; Mohammad Hosein Sanaati; Parisa Karimi; Massoud Houshmand; Homa Sadeghian; Leila Hashemi Chelavi
Journal:  Cell Mol Neurobiol       Date:  2008-08-26       Impact factor: 5.046

5.  High resolution HLA analysis reveals independent class I haplotypes and amino-acid motifs protective for multiple sclerosis.

Authors:  Steven J Mack; Julia Udell; Franziska Cohen; Kazutoyo Osoegawa; Sharon K Hawbecker; David A Noonan; Martha B Ladner; Damian Goodridge; Elizabeth A Trachtenberg; Jorge R Oksenberg; Henry A Erlich
Journal:  Genes Immun       Date:  2018-01-08       Impact factor: 2.676

6.  Genetic contribution to multiple sclerosis risk among Ashkenazi Jews.

Authors:  Pouya Khankhanian; Takuya Matsushita; Lohith Madireddy; Antoine Lizée; Lennox Din; Jayaji M Moré; Pierre-Antoine Gourraud; Stephen L Hauser; Sergio E Baranzini; Jorge R Oksenberg
Journal:  BMC Med Genet       Date:  2015-07-28       Impact factor: 2.103

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.